Glioblastoma  >>  depatuxizumab mafodotin (ABT-414)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
depatuxizumab mafodotin (ABT-414) / AbbVie
NCT01800695: Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme

Checkmark In glioblastoma multiforme
Jun 2016 - Jun 2016: In glioblastoma multiforme
Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Checkmark ASCO 2015
More
Completed
1
202
NA
ABT-414, Depatuxizumab Mafodotin, Temozolomide, Whole Brain Radiation
AbbVie
Glioblastoma Multiforme
06/17
06/17

Download Options